Predictive Oncology Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.455827 million compared to USD 0.313663 million a year ago. Net loss was USD 4.06 million compared to USD 5.44 million a year ago. Basic loss per share from continuing operations was USD 1 compared to USD 1.6 a year ago. Diluted loss per share from continuing operations was USD 1 compared to USD 1.6 a year ago.
For the nine months, sales was USD 1.14 million compared to USD 0.944187 million a year ago. Net loss was USD 17.82 million compared to USD 11.9 million a year ago. Basic loss per share from continuing operations was USD 5 compared to USD 4.6 a year ago. Diluted loss per share from continuing operations was USD 5 compared to USD 4.6 a year ago.